Janice Santos Cortes, MD
Urology · Providence, RINPI 1578705455
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Axonics, Inc. accounts for 67.9% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2021 at $8,470 and has fallen 91.0% since, to $760 in 2025.
Across 216 payments — averaging $57.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$8K
- Boston Scientific$1K
- Medtronic$515
- Valencia Technologies Corporation$344
- AbbVie$321
- Novo Nordisk$249
- plus $2K from 23 others
What the payments were for
- Consulting fees$5,00040%
- Speaking & faculty fees$4734%
- Travel & lodging$1,0869%
- Food & beverage$5,85747%
- Education$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 100 | $8,469 |
| Boston Scientific | 17 | $1,058 |
| Medtronic(2 entities) | 15 | $515 |
| Valencia Technologies Corporation | 3 | $344 |
| AbbVie(2 entities) | 15 | $321 |
| Novo Nordisk | 3 | $249 |
| Astellas Pharma US Inc | 12 | $249 |
| Neotract Inc. | 4 | $199 |
| Innovation Technologies Inc | 1 | $172 |
| Myriad Genetic Laboratories, Inc. | 8 | $161 |
| Coloplast | 7 | $107 |
| 180 Medical, Inc. | 2 | $104 |
| Urovant Sciences Inc | 4 | $70 |
| Laborie Medical Technologies Corp. | 3 | $55 |
| Abbott | 2 | $43 |
| Amgen | 2 | $41 |
| Myovant Sciences Inc. | 2 | $39 |
| Bayer | 2 | $37 |
| Merck | 2 | $37 |
| Tolmar Pharmaceuticals, Inc. | 2 | $36 |
| Exact Sciences | 2 | $32 |
| Smith+Nephew | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Pfizer | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| AstraZeneca | 1 | $14 |
| Hollister Incorporated | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics r-SNM System$6,851
- Axonics$510
- INTERSTIM$367
- Bulkamid$359
- eCoin Device Kit$306
- Irrisept$172
- SpaceOAR VUE System - 10mL$158
- ADVANTAGE FIT$124
- GENERAL PELVIC ORGAN PROLAPSE$111
How this compares
$12,468 in reported general payments places this provider in the 85th percentile of 55 urology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 241 | $159,742 |
| MyrbetriqMirabegron | 70 | $43,529 |
| Estradiol | 180 | $10,049 |
| Methenamine Hippurate | 54 | $4,579 |
| Tadalafil | 14 | $3,786 |
| Silodosin | 23 | $1,660 |
| Trospium Chloride | 23 | $799 |
| Desmopressin Acetate | 14 | $690 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 46 | $662 |
| NitrofurantoinNitrofurantoin Macrocrystal | 18 | $451 |
| Solifenacin Succinate | 16 | $402 |
| Tamsulosin Hcl | 56 | $399 |
| Ciprofloxacin Hcl | 48 | $278 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 12 | $155 |
| Finasteride | 27 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $18 | $159,742241 claims |
| Astellas Pharma US IncMyrbetriq | $249 | $43,52970 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 55 urology providers in Rhode Island.
Other urology in Providence
- Dicken KoProvidence$158K
- Gyan PareekProvidence$83K
- Joseph RenzulliProvidence$81K
- Simone ThavaseelanProvidence$16K
- Boris GershmanProvidence$13K
- Dragan GolijaninProvidence$11K
- Elias HyamsProvidence$10K
- Andrew TompkinsProvidence$3K
- Ashley MatthewProvidence$3K
- Gabriella AvellinoProvidence$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.